Upcoming Events at the San Diego Chapter

Chapter Homepage

Tuesday, October 10, 2006
6:00-8:00 p.m.

The San Diego Chapter of the Licensing Executives Society
Panel Discussion Featuring:

"Business Aspects of Regenerative Medicine"

Sponsored by:

SPEAKERS:
ERIC DANIEL, M.D. – DIRECTOR, BUSINESS DEVELOPMENT – CYTORI THERAPEUTICS, INC.
ALAN J. LEWIS, PH.D. – PRESIDENT, CHIEF EXECUTIVE OFFICER, AND DIRECTOR – NOVOCELL
EWA CARRIER, MD, MHS – ASSOCIATE PROFESSOR – MEDICINE & PEDIATRICS, BLOOD AND MARROW TRANSPLANTATION PROGRAM – UCSD CANCER CENTER

MODERATOR:
D. ELLIOT PARKS, PH.D. – MANAGING DIRECTOR – HAMILTON BIOVENTURES

PROGRAM DESCRIPTION:
As the regenerative medicine field is growing, it is making its mark worldwide.  The huge embryonic stem cell bank created by Medical Research Council (MRC) in Britain, licensing agreements between companies within the U.S. and those outside, and loans by philanthropic organizations to California Institute for Regenerative Medicine (CIRM) exemplify that this sector is blooming.  Locally, President George W. Bush's veto of legislation to expand federally funded embryonic stem cell research has resulted in state money flowing into this area.  Gov. Arnold Schwarzenegger decided to loan CIRM (created by proposition 71) $150 million in state money to jump start the program.

The pace of stem cell research and applications no doubt, is being determined by ethical, scientific, business and political considerations.  And interestingly enough, these factors continue to influence one another. Will the expansion of this exciting, yet at times elusive terrain be limited by IP factors, or will it be enhanced by them?  How will the IP developed from CIRM funding be commercialized and how will the rewards, if any, be shared with the California taxpayer?  What are the entities vying for a big piece of the CIRM $$$$ pie?  Could some of the claims that are being made by stem cell companies regarding treatments be extravagant, i.e., is the stem cell area a 20+ year work-in-progress with no significant therapeutic results for patients?

To learn more, please join us on October 10 at the Licensing Executives Society (LES) Meeting at La Jolla Marriott.

DATE:
Tuesday, October 10, 2006

TIME:
6:00 p.m. – 6:50 Registration, Networking, Cocktails and Appetizers
6:50 p.m. – 7:00 p.m. Chapter Business
7:00 p.m. – 8:00 p.m. Panel Discussion

LOCATION: 
Marriott San Diego La Jolla, 4240 La Jolla Village Drive

COST:
Pre-Register by 12 noon on Friday, October 6, 2006
 
$35 Members by Friday October 6, $45 at the door (cash or check only)
$40 Non-Members by Friday October 6,  $50 at the door (cash or check only)

$20 Member Student Rate, and $25 Non-Member Student Rate paid at the door
(cash or check only) until the website is setup for on line registration

REGISTRATION OPTIONS:
You have the option of registering online and paying either by credit card OR check

Pre-registration not only guarantees you a seat, but it also saves you $10.

LES Members, click here to register online with your credit card;

Non-Members, click here to register with your credit card;

Seating is limited and will be on a first come, first served basis.  Please note that we will still need to receive your check by Friday, October 6, to guarantee your registration. The address to mail your check to is:

Chris Steinhardt 

c/o Knobbe Martens Olson & Bear LLP
550 West C Street, Suite 1200
San Diego, CA 92101
619-235-8550  619-235-0176 Fax
e-mail: csteinhardt@kmob.com

For additional information, please contact:

NOTE:   This presentation will qualify for MCLE credit

PANELISTS’ BIOGRAPHIES

Eric Daniel, M.D. – Director, Business Development – Cytori Therapeutics, Inc. 

Dr. Daniels has served as Director of Business Development for Cytori Therapeutics since 2004. Previously, he held a position as a senior scientist at StemSource, Inc., before the company merged with Cytori, where he performed basic and applied research on adipose tissue-derived stem and regenerative cells. Dr. Daniels received both his MD and MBA from The University of California, Los Angeles.

Alan J. Lewis, Ph.D. – President, Chief Executive Officer, and Director – Novocell

Alan J. Lewis, Ph.D., joined Novocell in February 2006 as President, Chief Executive Officer, and Director. Prior to Novocell, Dr. Lewis served as CEO and Director of Signal Pharmaceuticals before its acquisition in 2000 by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases. He then served as President of the Signal Research Division at Celgene. Dr. Lewis previously held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis currently serves as a Director of BioMarin Pharmaceutical, Inc., and Cytochroma, Inc. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University.

Ewa Carrier, MD, MHS – Associate Professor – Medicine & Pediatrics, Blood and Marrow Transplantation Program – UCSD Cancer Center

Ewa Carrier, MD, was born in Poland. Her medical training has been international in scope, including studies in Poland, Hungary, Italy, England, and the Unites States. Residency and research fellowships at Stanford University Medical Center, Children's Medical Center in Northern California, and the Division of Pediatric Transplant Program at the University of California San Francisco culminated in a clinical faculty position at the Department of Pediatrics at UCSF. She later moved to the University of California San Diego in 1998 to establish her own laboratory. She is currently associated with the Blood and Marrow Transplant Program at UCSD. Her laboratory is dedicated to studying the biology of stem cells and their ability to trans-differentiate and repair tissues. Dr. Carrier has developed clinical programs to transplant autoimmune diseases, such as lupus erythematosus and Crohn's disease

D. Elliot Parks, Ph.D. – Managing Director – Hamilton BioVentures

D. Elliot Parks, Ph.D. is Managing Director with Hamilton BioVentures and has over 30 years experience in the life science industry.  Prior to joining Hamilton in 2005, he led Ventana Capital Management’s life science venture practice, serving as Managing Director.  Dr. Parks became involved in life sciences venture capital funding while serving as the Director of Johnson & Johnson Biotechnology Center more than 15 years ago.  A well-known figure in the San Diego biotechnology community, Dr. Parks served in key leadership positions at the Research Institute of Scripps Clinic and the Johnson & Johnson Biotechnology Center.   From 1996 through 1998, he was President  & Chief Executive Officer of Myelos Neurosciences in San Diego, and led that company from early stage formation through initiation of Phase 2 clinical trials of its lead compound.  After Myelos was successfully sold to a public biotechnology company, Dr. Parks entered institutional life sciences venture capital investing with Ventana.   Dr. Parks earned his Doctorate in cellular and molecular biology at the University of Washington, Seattle.   He is active in several key Industry advisory committees and Boards of Directors.

Pillsbury Winthrop Shaw Pittman LLP

Pillsbury Winthrop Shaw Pittman LLP is an international law firm with over 800 attorneys in 15 offices, including downtown San Diego and North County in Carmel Valley.  In business for more than 135 years, Pillsbury's practice focuses on capital markets and financial services, energy, intellectual property, global sourcing, litigation, real estate, technology, life sciences and communications.